---
figid: PMC4381889__cpaa-7-057Fig4
figtitle: 'KRAS-reprogrammed glutamine metabolism in pancreatic cancer.Notes: In KRAS-mutant
  pancreatic cancer, mitochondrial glutamine flux is reprogrammed to predominantly
  flux through GOT2, instead of the canonical GLUD1 pathway'
organisms:
- Mus musculus
- Microtus arvalis
- Homo sapiens
- Human papillomavirus type 16
pmcid: PMC4381889
filename: cpaa-7-057Fig4.jpg
figlink: /pmc/articles/PMC4381889/figure/f4-cpaa-7-057/
number: F4
caption: 'KRAS-reprogrammed glutamine metabolism in pancreatic cancer.Notes: In KRAS-mutant
  pancreatic cancer, mitochondrial glutamine flux is reprogrammed to predominantly
  flux through GOT2, instead of the canonical GLUD1 pathway. The Asp produced from
  this reaction is shuttled to the cytoplasm to produce pyruvate and NADPH from malate
  via cytosolic ME1. TCA cycle-derived malate can also produce NADPH from mitochondrial
  ME2. Wild-type p53 inhibits both ME1 and ME2. BPTES and CB-839 are non-competitive
  small-molecule inhibitors of mitochondrial GLS1.Abbreviations: GOT2, mitochondrial
  aspartate transaminase; GLUD1, glutamate dehydrogenase 1; Asp, aspartate; NADPH,
  nicotinamide adenine dinucleotide phosphate; ME1, malic enzyme 1; ME2, malic enzyme
  2; BPTES, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3; GLS1,
  glutaminase 1; MDH1, malate dehydrogenase 1; GOT1, cytosolic aspartate transaminase;
  OAA, oxaloacetate; αKG, α-ketoglutarate; TCA, tricarboxylic acid cycle.'
papertitle: Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide
  adenine dinucleotide phosphate-biogenesis pathways.
reftext: Gaurab Chakrabarti, et al. Clin Pharmacol. 2015;7:57-68.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.931605
figid_alias: PMC4381889__F4
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC4381889__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4381889__cpaa-7-057Fig4.html
  '@type': Dataset
  description: 'KRAS-reprogrammed glutamine metabolism in pancreatic cancer.Notes:
    In KRAS-mutant pancreatic cancer, mitochondrial glutamine flux is reprogrammed
    to predominantly flux through GOT2, instead of the canonical GLUD1 pathway. The
    Asp produced from this reaction is shuttled to the cytoplasm to produce pyruvate
    and NADPH from malate via cytosolic ME1. TCA cycle-derived malate can also produce
    NADPH from mitochondrial ME2. Wild-type p53 inhibits both ME1 and ME2. BPTES and
    CB-839 are non-competitive small-molecule inhibitors of mitochondrial GLS1.Abbreviations:
    GOT2, mitochondrial aspartate transaminase; GLUD1, glutamate dehydrogenase 1;
    Asp, aspartate; NADPH, nicotinamide adenine dinucleotide phosphate; ME1, malic
    enzyme 1; ME2, malic enzyme 2; BPTES, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl
    sulfide 3; GLS1, glutaminase 1; MDH1, malate dehydrogenase 1; GOT1, cytosolic
    aspartate transaminase; OAA, oxaloacetate; αKG, α-ketoglutarate; TCA, tricarboxylic
    acid cycle.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Decr1
  - Me1
  - Tcf12
  - Mdh1
  - Kras
  - Glud1
  - Grid1
  - Got1
  - Got2
  - Gnat2
  - Trp53
  - Me2
  - Tcf4
  - Tcf3
  - DECR1
  - ME1
  - PCDHB16
  - GLS
  - MDH1
  - KRAS
  - NRAS
  - GLUD1
  - GRID1
  - GOT1
  - GOLT1B
  - GOLT1A
  - GOT2
  - TP53
  - TP63
  - TP73
  - ME2
  - CELSR1
  - PCDHB11
  - Asp
  - Glutamine
  - Pyruvate
  - Glutamate
---
